BCLP Inhibitors
BCLP inhibitors are a class of chemical compounds designed to target and inhibit the function of the BCLP protein, a member of the B-cell lymphoma protein family involved in various cellular processes such as apoptosis regulation and intracellular signaling. BCLP is known to participate in the regulation of cell survival by modulating pro- and anti-apoptotic signaling pathways, often through interactions with other members of the BCL family. By inhibiting BCLP, these compounds disrupt its role in maintaining the balance between cell death and survival, affecting how cells respond to stress signals and apoptosis triggers. BCLP inhibitors are valuable tools for investigating the molecular mechanisms that govern cell death regulation and for understanding the intricacies of the signaling pathways controlled by the BCL family.
The design of BCLP inhibitors typically focuses on targeting specific domains within the BCLP protein that are critical for its interactions with other proteins in apoptotic pathways, such as its BH3 domain. These inhibitors are often optimized through structure-activity relationship (SAR) studies to enhance their specificity and affinity for BCLP, ensuring minimal off-target effects. BCLP inhibition allows researchers to explore the role of this protein in broader cellular functions, such as its influence on mitochondrial dynamics, intracellular signaling, and stress response pathways. Additionally, these inhibitors provide insight into how BCLP interacts with other members of the BCL family, helping to clarify the complex network of regulatory interactions that control apoptosis and cellular homeostasis. By using BCLP inhibitors, researchers can better understand the balance between survival and cell death, offering insights into the molecular underpinnings of these essential processes.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 targets the BCL-2 family of proteins, to which BCLP belongs. It mimics BH3-only proteins, which are natural inhibitors of BCL-2 proteins, promoting apoptosis by preventing BCLP from sequestering pro-apoptotic factors. | ||||||
ABT 263 | 923564-51-6 | sc-207241 | 5 mg | $240.00 | 16 | |
ABT 263 binds with high affinity to BCL-2 family proteins including BCLP. It displaces pro-apoptotic proteins like BIM, enabling these proteins to initiate apoptosis, thereby inhibiting the anti-apoptotic function of BCLP. | ||||||
Obatoclax Mesylate | 803712-79-0 | sc-364221 sc-364221A | 5 mg 10 mg | $94.00 $138.00 | ||
Obatoclax is a pan-BCL-2 inhibitor that can neutralize the function of BCLP by occupying its BH3 binding groove, which is essential for its anti-apoptotic activity, leading to the induction of apoptosis in cells reliant on BCLP. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $114.00 $225.00 | 12 | |
Gossypol, a natural compound from cottonseed, binds to the BH3 domain of BCL-2 family proteins including BCLP, thereby inhibiting its anti-apoptotic activity and promoting cell death through apoptosis. | ||||||
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $200.00 | 54 | |
ABT 737 is a BH3 mimetic that binds to BCL-2, BCL-XL, and BCLP with high affinity, displacing pro-apoptotic BH3-only proteins, thus inhibiting the anti-apoptotic activity of BCLP and promoting apoptosis. | ||||||
TW-37 | 877877-35-5 | sc-361387 sc-361387A | 10 mg 50 mg | $200.00 $860.00 | 2 | |
TW-37 binds to the BH3 binding groove of BCL-2 family proteins, including BCLP, thereby inhibiting BCLP's interaction with pro-apoptotic proteins and promoting apoptosis by freeing these pro-apoptotic factors. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine is known to induce apoptosis by disrupting the mitochondrial membrane potential, which is regulated by BCLP. This leads to the release of cytochrome c and subsequent apoptosis, thereby diminishing BCLP's function. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $105.00 | 22 | |
AG 1024 interacts with the BH3 binding site of BCL-2 family proteins, including BCLP, blocking their ability to bind pro-apoptotic proteins, thus leading to apoptosis and a reduction in the anti-apoptotic activity of BCLP. | ||||||
AS703026 | 1236699-92-5 | sc-364412 sc-364412A | 5 mg 10 mg | $80.00 $130.00 | ||
A-1155463 is a highly potent and selective BCL-2 inhibitor that binds to the BH3 site of BCLP, antagonizing its anti-apoptotic function and promoting apoptosis in cells dependent on BCLP for survival. | ||||||
S-55746 | 1448584-12-0 | sc-507289 | 10 mg | $750.00 | ||
S55746/BCL201 is a selective BCL-2 inhibitor that binds to BCLP with high affinity, disrupting its function and triggering apoptosis by releasing pro-apoptotic factors that BCLP would otherwise sequester. | ||||||